Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia

NCT05399693 is registered in ClinicalTrials.gov with Institut de cancérologie Strasbourg Europe as lead sponsor.

NCT NCT05399693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia
Lead sponsor
Institut de cancérologie Strasbourg Europe
Phase
Observational
Overall status
Completed
Start date
February 2, 2022
Completion date
August 8, 2023
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

platelet transfusion refractoriness